Form Type: 4

SEC EDGAR Link
Accession Number:0001367644-21-000047
Date:2021-02-24
Issuer: EMERGENT BIOSOLUTIONS INC. (EBS)
Original Submission Date:

Reporting Person:

HAVEY ADAM
400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG, MD 20879

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2021-02-24 A 3,744 a $0.00 36,764 direct
COMMON STOCK 2021-02-24 A 3,744 a $0.00 40,508 direct
COMMON STOCK 2021-02-24 F 847 d $93.49 39,661 direct
COMMON STOCK 2021-02-26 F 739 d $97.15 38,922 direct
COMMON STOCK 2021-02-26 F 732 d $97.15 38,190 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTIONS (RIGHT TO BUY) 93.49 2021-02-24 deemed execution date A 14,973 (a) 2028-02-23 common stock 14,973 $93.49 14,973 direct
Footnotes
IDfootnote
f1 consists of restricted stock units granted under the company's stock incentive plan. these restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. each restricted stock unit represents the right of the reporting person to receive one share of common stock of emergent biosolutions inc., subject to adjustment as provided in the grant agreement.
f2 consists of performance stock units granted under the emergent biosolutions inc. stock incentive plan. each psu represents a right to receive one share of common stock. the psus vest upon achievement with respect to adjusted ebitda margin calculated on a cumulative basis over the three-year period beginning january 1, 2021 and ending december 31, 2023, as certified by the compensation committee following the performance period. the amount reported is based on the target performance payout factor, or 100%.
f3 represents shares of common stock withheld to pay taxes.
f4 vests in three equal installments beginning on the day prior to the anniversary date of the grant.
WhaleWisdom Logo

Elevate your investments